公开(公告)号：US10174081B2

公开(公告)日：2019-01-08

申请号：US14113158

申请日：2012-04-20

申请人： Barney Bishop ,  Monique van Hoek

发明人： Barney Bishop ,  Monique van Hoek

IPC分类号： C07K14/00 ,  C07K7/06 ,  A01N37/46 ,  C07K7/08 ,  C07K14/47 ,  C12Q1/18 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/17

摘要： Materials and methods for making and using cationic anti-microbial peptides (CAMPs), and compositions containing such peptides.

公开(公告)号：US08404636B2

公开(公告)日：2013-03-26

申请号：US12502420

申请日：2009-07-14

申请人： Barney Bishop ,  Monique van Hoek ,  Keith M. Davies

发明人： Barney Bishop ,  Monique van Hoek ,  Keith M. Davies

IPC分类号： A61K38/08

CPC分类号： A61K47/64 ,  A61K31/15 ,  A61K31/165 ,  A61K31/5383 ,  A61K47/645

摘要： A cationic antimicrobial peptide (CAMP) conjugate is disclosed. The CAMP conjugate may be made by identifying a suitable carrier peptide; identifying a suitable antimicrobial agent; creating a conjugate by conjugating the peptide with the antimicrobial agent; and evaluating and refining the conjugate. The peptide may be short peptide based on the sequence of a CAMP, such as human β-defensin-3. The peptide can be directly connected to the antimicrobial agent or through a linker segment. The antimicrobial agent may be connected to the peptide or the linker segment through stable or cleavable bonding. The peptide may carry and facilitate the delivery of the conjugated antimicrobial agent to a microbe.

摘要翻译： 公开了一种阳离子抗微生物肽（CAMP）缀合物。 可以通过鉴定合适的载体肽来制备CAMP缀合物; 鉴定合适的抗微生物剂; 通过将肽与抗微生物剂缀合而产生结合物; 并评估和改良缀合物。 肽可以是基于CAMP的序列的短肽，例如人和防腐素-3。 肽可以直接连接到抗微生物剂或通过接头片段。 抗微生物剂可以通过稳定或可切割的结合连接到肽或接头片段。 肽可以携带和促进缀合的抗微生物剂递送到微生物。

公开(公告)号：US07718619B2

公开(公告)日：2010-05-18

申请号：US12202096

申请日：2008-08-29

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/00 ,  A61K51/00 ,  A61K31/785 ,  G01N33/53 ,  G01N33/00

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US07678771B2

公开(公告)日：2010-03-16

申请号：US12202146

申请日：2008-08-29

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/00 ,  A61K51/00 ,  A61K31/785 ,  G01N33/53 ,  G01N33/00

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US07678770B2

公开(公告)日：2010-03-16

申请号：US12201739

申请日：2008-08-29

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/00 ,  A61K51/00 ,  A61K31/785 ,  G01N33/53 ,  G01N33/00

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US07659253B2

公开(公告)日：2010-02-09

申请号：US12131923

申请日：2008-06-02

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/00 ,  A61K51/00 ,  A61K31/785 ,  G01N33/53 ,  G01N33/00

CPC分类号： A61K31/27 ,  A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US20090186828A1

公开(公告)日：2009-07-23

申请号：US12239087

申请日：2008-09-26

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/06 ,  A61K31/165 ,  A61K38/05

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y02A50/415 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US20090137489A1

公开(公告)日：2009-05-28

申请号：US12203132

申请日：2008-09-02

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/08 ,  C07C229/02 ,  C07K5/06 ,  C07K5/08 ,  C07K5/10 ,  C07K7/06 ,  A61P25/00 ,  A61K31/198 ,  A61K38/05 ,  A61K38/06 ,  A61K38/07

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

公开(公告)号：US20090137487A1

公开(公告)日：2009-05-28

申请号：US12202941

申请日：2008-09-02

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K38/08 ,  A61K38/05 ,  A61K38/06 ,  A61P25/28 ,  A61K31/198 ,  A61K38/07

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.

摘要翻译： 本发明描述了使用包含与苯丙胺共价连接的化学部分的化合物，组合物和方法。 这些化合物和组合物可用于减少或预防滥用和过量安非他明。 这些化合物和组合物特别用于提供某些障碍（例如注意力缺陷多动障碍（ADHD），ADD，发作性睡病和肥胖）的耐药性替代治疗。 苯丙胺的口服生物利用度维持在治疗有用的剂量。 在较高剂量下，生物利用度显着降低，从而提供减少口服滥用责任的方法。 此外，本发明的化合物和组合物通过肠胃外途径（例如静脉内或鼻内给药）降低苯丙胺的生物利用度，进一步限制其滥用责任。

公开(公告)号：US20090131534A1

公开(公告)日：2009-05-21

申请号：US12201907

申请日：2008-08-29

申请人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

发明人： Travis Mickle ,  Suma Krishnan ,  Barney Bishop ,  Christopher Lauderback ,  James Scott Moncrief ,  Robert Oberlender ,  Thomas Piccariello ,  Bernhard J. Paul ,  Christopher A. Verbicky

IPC分类号： A61K31/135

CPC分类号： A61K31/165 ,  A61K47/542 ,  C07C237/06 ,  Y10S436/901 ,  Y10T436/173845

摘要： The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.